[8-K] 60 Degrees Pharmaceuticals, Inc. Warrant Reports Material Event

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Analyzing...

07/18/2025 - 04:57 PM

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

60 Degrees Pharm

NASDAQ:SXTPW

SXTPW Rankings

N/A Ranked by Market Cap

N/A Ranked by Dividends

SXTPW Latest News

Jul 17, 2025

60 Degrees Pharmaceuticals and Tulane University Sign Research Agreement to Study Tafenoquine Against Lyme and Bartonella Bacteria

Jul 16, 2025

60 Degrees Pharmaceuticals Announces Closing of up to $10 Million Public Offering

Jul 15, 2025

60 Degrees Pharmaceuticals Announces Pricing of Up to $10 Million Public Offering

Jul 15, 2025

60 Degrees Pharmaceuticals Defines Potential Human Babesiosis Market Size for ARAKODA® (tafenoquine): Annual Max TAM, Sales of $245 Million; Cumulative through Patent Expiration, $1.1 Billion

Jul 14, 2025

60 Degrees Pharmaceuticals to Submit MUMS (Minor Use/Minor Species) Designation Request to FDA for Tafenoquine for Acute Canine Babesiosis in 2025

SXTPW Latest SEC Filings

Jul 18, 2025

[SCHEDULE 13G] 60 Degrees Pharmaceuticals, Inc. Warrant SEC Filing

Jul 17, 2025

[SCHEDULE 13G/A] 60 Degrees Pharmaceuticals, Inc. Warrant SEC Filing

Jul 17, 2025

[SCHEDULE 13G] 60 Degrees Pharmaceuticals, Inc. Warrant SEC Filing

Jul 16, 2025

[424B4] 60 Degrees Pharmaceuticals, Inc. Warrant Prospectus Filed Pursuant to Rule 424(b)(4)

Jul 7, 2025

[S-1] 60 Degrees Pharmaceuticals, Inc. Warrant Files IPO Registration Statement

SXTPW Stock Data

Float 1.47M

Industry Medicinal and Botanical Manufacturing

Sector Pharmaceutical Preparations

City WASHINGTON